Please assess the completion status of the following clinical trial:

Trial Title: Trial of Aggressive Hydration Versus Rectal Indomethacin for Prevention of Post-ERCP Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients aged 18 to 70 years undegoingt ERCP for the first time~* Patients undergoing ERCP for standard clinical indications~Exclusion Criteria:~* Ongoing acute pancreatitis~* Known chronic calcific pancreatitis~* Pancreatic head mass~* Any malignancy~* Standard contraindications to ERCP~* Unwillingness or inability to consent for the study~* Ongoing hypotension including those with sepsis~* Cardiac insufficiency (CI, \>NYHA Class II heart failure)~* Renal insufficiency (RI, creatinine clearance \<40mL/min)~* Severe liver dysfunction (albumin \< 3mg/dL)~* Respiratory insufficiency (defined as oxygen saturation \< 90%)~* Greater than 70 years of age~* Pregnancy~* Breastfeeding mother~* Allergy/hypersensitivity to aspirin or NSAIDs~* Received NSAIDs in prior 7 days (aspirin 325mg or less ok)~* Active or recurrent (within 4 weeks) gastrointestinal hemorrhage~* Hyponatremia (Na+ levels \< 135mEq/L))~* Hypernatremia (Na+ levels \> 150mEq/L) will be excluded.~* Edema or anasarca~* Ascites~* Procedure performed on major papilla/ventral pancreatic duct in patient with pancreas divisum (dorsal duct not attempted on injected)~* ERCP for biliary stent removal or exchange without anticipated pancreatogram~* Subject with prior biliary sphincterotomy now scheduled for repeat biliary therapy without anticipated pancreatogram~* Anticipated inability to follow protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Aggressive Hydration (Type: EXPERIMENTAL): Patients randomized to the aggressive intravenous hydration group received Lactated Ringers solution (LR) \[COMPOUND SODIUM LACTATE INJECTION I.P.,INVEN PHARMACEUTICALS PVT.LTD,MP,INDIA\] intravenously (IV) at 3 mL/kg/hr during the ERCP, a 20cc/kg IV bolus immediately afterward, and then at 3 mL/kg/hr for 8 hours following the procedure.
- Rectal Indomethacin (Type: ACTIVE_COMPARATOR): Patients randomised to Rectal Indomethacin were administered a suppository of 100 mg of indomethacin \[Indomethacin Suppository 100 Mg B.P, GALEN PHARMACEUTICAL LTD, GUJRAT, INDIA\] just after the completion of ERCP procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).